Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. Ultimately, the partnership will focus on advancing novel COMT inhibitor candidates into the clinic.
“Psychiatric disorders including cognitive impairment in schizophrenia have historically been difficult indications to treat and continue to remain areas of high unmet need. This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By combining our expertise, we hope to make significant steps forward to finding solutions for patients for which there currently is no treatment.”
COMT, a dopamine metabolizing enzyme, is key to the modulation of dopamine in the prefrontal cortex and hippocampus of the brain. Adequate function of dopamine signaling is critical for a number of cognitive and behavioral processes that are impaired in a variety of neuropsychiatric and neurological disorders such as schizophrenia. While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.
Recent studies from the Lieber Institute suggest an important role of centrally acting COMT inhibitors in the potential symptomatic treatment of various neurological and neuropsychiatric disorders. The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds. In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.
“The Lieber Institute has a long-standing effort exploring centrally acting COMT inhibitors as part of its mission to understand the genetic and molecular mechanisms of schizophrenia and related brain disorders,” said Daniel R. Weinberger, M.D., LIBD CEO & Director. “We are excited to embark on this partnership with Boehringer Ingelheim to identify potential therapeutic candidates and advance them to clinical development in order to help improve the lives of those affected by this serious mental health condition.”
Financial details of the collaboration were not disclosed.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-libd
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005641/en/
Contact information
Media Contacts
Sarah Soetbeer
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77 183874
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
Jean DuBose
Lieber Institute for Brian Development
media@libd.org
P: +1 443-676-4363
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 08:20:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance23.10.2025 08:00:00 EEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio. Record net sales of 3.737 billion USD for the first nine months of the year, representing net sales growth of 15.0% at constant currency1, despite challenging market dynamics, driven primarily by volume growth complemented by favorable mix Widespread growth with acceleration across all geographies and product categories, including Injectable Aesthetics (+10.5%) with some phasing benefits in Neuromodulators, Dermatological Skincare (+8.2%), and Therapeutic Dermatology (+40.4%), all year-on-year for the first nine months of 2025 at constant currency Advancing future growth drivers across the portfolio, led by the strong commercial momentum of Nemluvio® as well as the ramp-up of multiple launches in flagship brands across Injectable Aesthetics
IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors22.10.2025 23:15:00 EEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/ Brett Icahn (Photo: IFF) These appointments follow the company’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Hernández stepped down from the board on Oct. 20. Icahn has been named to the Board’s Audit Committee and Transaction Committee, and Mulligan has been named to the Board’s Innovation Committee. “We are very pleased to welcome Brett and Richard to the IFF board,” said Kevin O’Byrne, chair of the IFF boa
OpenAI, Oracle and Vantage Data Centers Announce Stargate Data Center Site in Wisconsin22.10.2025 23:05:00 EEST | Press release
OpenAI, Oracle and Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced plans to develop a data center campus outside Milwaukee in Port Washington, Wisconsin. The new campus is part of OpenAI and Oracle’s previously announced partnership to invest up to 4.5 gigawatts of additional Stargate capacity and is the Midwest site that was recently announced as part of OpenAI’s Stargate expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022873578/en/ Vantage Data Centers’ $15B+ campus in Port Washington, Wisconsin represents the future of sustainable digital infrastructure. The campus will feature four cutting-edge data centers providing close to a gigawatt of AI capacity. Construction will begin soon and is scheduled for completion in 2028. The project expects to create more than 4,000 skilled construction jobs, most of which will be union jobs. Once complete, Vantage and Orac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom